LON:AVO Advanced Oncotherapy (AVO) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Advanced Oncotherapy Stock (LON:AVO) 30 days 90 days 365 days Advanced Chart Get Advanced Oncotherapy alerts:Sign Up Key Stats Today's Range N/A50-Day Range 1.75▼ 1.7552-Week Range N/AVolume200,000 shsAverage Volume1.27 million shsMarket Capitalization£9.50 millionP/E RatioN/ADividend Yield5.49%Price TargetN/AConsensus RatingN/A Company Overview Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom. Read More Receive AVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Advanced Oncotherapy and its competitors with MarketBeat's FREE daily newsletter. Email Address AVO Stock News HeadlinesOzarks Healthcare Partners with Avo to Integrate AI-Powered Decision Support in the EHROctober 18, 2024 | tmcnet.comAVO.L Regulatory NewsAugust 22, 2024 | lse.co.ukThis Cold War “Accident” Could Unleash New $100 Trillion AI BoomObscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered. | Brownstone Research (Ad)Advanced Oncotherapy Share ChatJanuary 23, 2024 | lse.co.ukAdvanced Oncotherapy PLC AVODecember 9, 2023 | morningstar.comMFavourable Signals For Advanced Oncotherapy: Numerous Insiders Acquired StockJune 12, 2023 | finance.yahoo.comFavourable Signals For Advanced Oncotherapy: Numerous Insiders Acquired Stock \June 12, 2023 | finance.yahoo.comHardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to dateJanuary 27, 2023 | finanznachrichten.deSee More Headlines AVO Stock Analysis - Frequently Asked Questions How were Advanced Oncotherapy's earnings last quarter? Advanced Oncotherapy plc (LON:AVO) released its quarterly earnings results on Monday, June, 29th. The company reported ($9.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($8.90) by $0.93. How do I buy shares of Advanced Oncotherapy? Shares of AVO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Advanced Oncotherapy own? Based on aggregate information from My MarketBeat watchlists, some other companies that Advanced Oncotherapy investors own include UK Oil & Gas (UKOG), Academy Sports and Outdoors (ASO), Renishaw (RSW), Tullow Oil (TLW), BMR Group (BMR), Lancashire (LRE) and Sirius Minerals (SXX). Company Calendar Last Earnings6/29/2020Today7/14/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryAgriculture Current SymbolLON:AVO CIKN/A Webwww.advancedoncotherapy.com Phone+44-20-36178728FaxN/AEmployees3,900Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£32.60 million Net MarginsN/A Pretax MarginN/A Return on Equity-67.34% Return on Assets-11.73% Debt Debt-to-Equity Ratio98.71 Current Ratio1.26 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow33.50 Book ValueGBX 14 per share Price / BookN/AMiscellaneous Outstanding Shares542,570,000Free FloatN/AMarket Cap£9.50 million OptionableNot Optionable Beta0.06 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (LON:AVO) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Advanced Oncotherapy plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Advanced Oncotherapy With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.